BIOCEPT INC BIOC Income Statement

Biocept inc (BIOC)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Jun'13	Mar'13
Net revenues
5,950	5,528	4,604	3,836	3,467	3,250	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net revenues
-	-	-	-	-	3,250	-	-	-	5,068	5,365	5,300	4,684	3,223	2,149	1,267	681	609	467	312	255	133	0	0	0	0	0
Costs and expenses:
Cost of revenues
11,325	10,977	10,540	10,189	10,216	10,051	9,976	9,981	9,650	9,345	8,884	8,273	7,574	6,920	6,296	5,579	4,923	4,596	3,935	3,313	2,659	2,170	0	0	0	0	0
Gross loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Research and development expenses
4,786	4,697	4,824	4,750	4,621	4,468	4,088	3,855	3,678	3,364	3,124	2,868	2,742	2,713	2,829	2,906	2,934	2,857	3,143	3,776	4,140	4,497	0	0	0	0	0
General and administrative expenses
7,192	6,970	6,691	6,784	6,817	7,074	7,091	7,132	7,221	7,189	7,176	7,260	6,979	6,560	6,327	6,040	5,881	5,686	5,513	4,943	4,617	5,201	0	0	0	0	0
Sales and marketing expenses
6,031	5,940	5,892	5,834	5,652	5,914	6,116	6,388	6,702	6,343	5,880	5,482	5,027	5,054	5,139	4,916	4,475	3,880	3,506	3,263	2,835	2,137	0	0	0	0	0
Total costs and expenses
29,335	28,585	27,948	27,558	27,307	27,509	27,273	27,357	27,252	26,243	25,065	23,885	22,324	21,248	20,592	19,442	18,215	17,020	16,013	0	0	-	0	-	-	-	-
Loss from operations
-23,384	-23,056	-23,344	-23,722	-23,839	-24,258	-23,887	-23,622	-23,059	-21,174	-19,700	-18,584	-17,640	-18,025	-18,443	-18,175	-17,533	-16,410	-15,631	-14,984	-13,997	-13,873	0	0	0	0	0
Other expense:
Interest expense
244	249	267	269	290	310	328	352	482	482	518	584	469	525	538	559	628	639	643	619	544	1,789	0	0	0	0	0
Warrant inducement expense
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant inducement and other expenses
-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	200	0	0	0	0	0
Other income
-	-	-	-	-	-	-	-	-	-	-	-	153	153	153	140	0	-	0	0	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Total other expense
-4,177	-2,081	-2,092	-2,070	-290	-310	-334	-369	-469	-431	-428	-469	-316	-372	-384	-405	-487	-537	-579	-590	-538	-1,990	0	0	0	0	0
Loss before income taxes
-27,562	-25,138	-25,436	-25,793	-24,130	-24,569	-24,221	-23,991	-23,529	-21,606	-20,129	-19,053	-17,956	-18,397	-18,827	-18,580	-18,021	-16,947	-16,211	-15,575	-14,536	-15,864	0	0	0	0	0
Income tax expense
-	-	-	-	-	-	-	-	-	-	0	0	-	2	2	2	2	1	2	0	0	-	-	0	-	0	0
Net loss and comprehensive loss
-27,562	-25,138	-25,438	-25,794	-24,131	-24,571	-24,223	-23,997	-23,537	-21,613	-20,134	-19,055	-17,956	-18,399	-18,829	-18,583	-18,023	-16,949	-16,213	-15,577	-14,538	-15,866	0	0	0	0	0
Deemed dividend related to warrants down round provision
24	121	736	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common shareholders
-27,587	-25,259	-25,538	-26,531	-24,868	-25,207	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic
78,999	29,128	23,018	20,466	9,792	4,209	2,767	2,280	1,911	-19,190	986	901	20,969	15,673	8,370	7,702	6,566	-12,562	6,242	17,998	10,372	4,474	4,449	4,449	2,617	182	180
Diluted
78,999	29,128	23,018	20,466	9,792	4,209	2,759	2,280	1,911	-19,190	986	901	20,969	15,673	8,370	7,702	6,566	-12,562	6,242	17,998	10,372	4,474	4,449	4,449	2,617	182	180
Net loss per common share:
Basic
-0.11	-0.20	-0.25	-0.38	-0.61	-1.43	-2.42	-2.70	-3.33	-11.15	-5.90	-6.32	-0.21	-0.01	-0.57	-0.60	-0.74	-1.76	-0.72	-0.22	-0.37	-0.47	-0.87	-0.67	-1.96	-10.83	-10.67
Diluted
-0.11	-0.20	-0.25	-0.38	-0.61	-1.43	-2.42	-2.70	-3.33	-11.15	-5.90	-6.32	-0.21	-0.01	-0.57	-0.60	-0.74	-1.76	-0.72	-0.22	-0.37	-0.47	-0.87	-0.67	-1.96	-10.83	-10.67